140 related articles for article (PubMed ID: 37093359)
1. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
Rajasingham R; Enns EA; Khoruts A; Vaughn BP
Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
[TBL] [Abstract][Full Text] [Related]
4. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
[TBL] [Abstract][Full Text] [Related]
6. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transplantation for treatment of refractory or recurrent
Lan KY; Le PH; Chiu CT; Chen CC; Yeh YM; Cheng HT; Kuo CJ; Chen CL; Chen YC; Yeh PJ; Chiu CH; Chang CJ
Front Med (Lausanne); 2023; 10():1229148. PubMed ID: 37849493
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Feuerstadt P; Allegretti JR; Dubberke ER; Guo A; Harvey A; Yang M; Garcia-Horton V; Fillbrunn M; Tillotson G; Bancke LL; LaPlante K; Garey KW; Khanna S
Infect Dis Ther; 2024 Jan; 13(1):221-236. PubMed ID: 38236515
[TBL] [Abstract][Full Text] [Related]
9. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Berenson CS; Lashner B; Korman LY; Hohmann E; Deshpande A; Louie TJ; Sims M; Pardi D; Kraft CS; Wang EEL; Cohen SH; Feuerstadt P; Oneto C; Misra B; Pullman J; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Lee CH
Clin Infect Dis; 2023 Nov; 77(11):1504-1510. PubMed ID: 37539715
[TBL] [Abstract][Full Text] [Related]
11. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
J Clin Gastroenterol; 2023 Nov; ():. PubMed ID: 38019088
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.
Takeshima T; Sakai F; Wang X; Yamato K; Kojima Y; Zhang Y; Bennison C; Simons MJHG
Pharmacoeconomics; 2024 Jul; 42(7):811-822. PubMed ID: 38771521
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
16. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA
Knapple WL; Yoho DS; Sheh A; Thul J; Feuerstadt P
Therap Adv Gastroenterol; 2024; 17():17562848241239547. PubMed ID: 38529070
[TBL] [Abstract][Full Text] [Related]
17. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Lavoie T; Appaneal HJ; LaPlante KL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
[TBL] [Abstract][Full Text] [Related]
18. Live Biotherapeutic Products for the Prevention of Recurrent
Pettit NN; Shaeer KM; Chahine EB
Ann Pharmacother; 2024 Mar; ():10600280241239685. PubMed ID: 38546138
[TBL] [Abstract][Full Text] [Related]
19. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.
Gonzales-Luna AJ; Carlson TJ; Garey KW
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S487-S496. PubMed ID: 38051970
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
